Get the Stockscreener App
1.483
0.47%
-0.007
Nls Pharmaceutics Ltd stock is traded at $1.483, with a volume of 13,029.
It is down -0.47% in the last 24 hours and down -7.31% over the past month.
See More
Previous Close:
$1.49
Open:
$1.4537
24h Volume:
13,029
Relative Volume:
0.01
Market Cap:
$6.02M
Revenue:
-
Net Income/Loss:
$-15.47M
P/E Ratio:
-2.966
EPS:
-0.5
Net Cash Flow:
$-13.51M
1W Performance:
+14.08%
1M Performance:
-7.31%
6M Performance:
-69.73%
1Y Performance:
-75.96%
1-Day Range:
$1.45
$1.56
1-Week Range:
$1.38
$1.59
52-Week Range:
$1.30
$18.39
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Compare NLSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.483 | 6.02M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Nls Pharmaceutics Ltd Stock (NLSP) Latest News
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest - ACCESS Newswire
What's Going On With NLS Pharmaceutics Shares Monday? - Benzinga
NLS Pharmaceutics Secures $3 Million Financing and $25 Million Equity Facility - TipRanks
NLS Pharmaceutics secures $2M for Kadimastem merger - Investing.com
NLS Pharmaceutics secures $2M for Kadimastem merger By Investing.com - Investing.com Canada
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement - StreetInsider
Major Funding Breakthrough: NLS Pharmaceutics Raises $28M for Revolutionary ALS Treatment Development - Stock Titan
NLSP stock touches 52-week low at $1.47 amid market challenges By Investing.com - Investing.com South Africa
NLSP stock touches 52-week low at $1.47 amid market challenges - Investing.com India
NLS Pharmaceutics Ltd. (NASDAQ:NLSPW) Short Interest Down 31.6% in February - Defense World
NLS Pharmaceutics announces merger with Kadimastem By Investing.com - Investing.com Canada
NLS Pharmaceutics Announces Strategic Merger and Advances in Therapeutic Pipeline - TipRanks
NLS Pharmaceutics CEO Issues Letter to Shareholders - Quantisnow
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - Marketscreener.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline - Investing.com
NLSP stock touches 52-week low at $1.71 amid steep annual decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq - ACCESS Newswire
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement - ACCESS Newswire
AEX-2 increases total wake duration in mouse model - BioWorld Online
NLS Pharmaceutics Announces $20 Million Standby Equity Distribution Agreement and $2.5 Million Equity Investment - ACCESS Newswire
NLS Pharmaceutics reports progress in narcolepsy treatment By Investing.com - Investing.com South Africa
NLS Pharmaceutics reports progress in narcolepsy treatment - Investing.com
Can NLS Pharmaceutics' Orexin Agonist Treat More Than Just Sleep Disorders? New Data Says Yes - StockTitan
NLS Pharmaceutics and Partners Achieve Milestone in Diabetes Treatment Development - MSN
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment - PR Newswire
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder - ACCESS Newswire
NLS Pharmaceutics And Kadimastem Unveil Multi-Target Diabetes Approach - Nasdaq
Is NLSP’s price to cash per share ratio a concern for investors? - US Post News
NLS Pharmaceutics Ltd’s Shares Reel: -37.16% Quarterly Revenue Decline Amid 6.35M Market Cap - The InvestChronicle
NLS Pharmaceutics Ltd (NLSP) Shares Rise Despite Market Challenges - The News Heater
Stock market today: Patriot National Bancorp +46.21%, NLS Pharmaceutics +37.43% among top gainers in early trading - Business Upturn
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies - GuruFocus.com
NLS Pharmaceutics (NLSP) Shares Surge As Market Reacts To Potential Merger - Stocks Telegraph
NLS Pharmaceutics and Kadimastem Announce Merger to Innovate Diabetes Treatment - TipRanks
NLS and Kadimastem to merge, aim for diabetes care innovation - Investing.com
Are NLS Pharmaceutics Ltd’shares a good deal? - US Post News
Navigating NLSP Stock: NLS Pharmaceutics Ltd Journey - The InvestChronicle
NLS Pharmaceutics Ltd (NASDAQ: NLSP) Defies Bearish Expectations and Displays Strong Future Potential - Marketing Sentinel
NLS and Kadimastem move forward with merger plans - MSN
Israeli startup Kadimastem to merge With NLS Pharmaceutics - MSN
NLS Pharmaceutics to Participate in the 23rd Annual H.C. Wainwright Global Investment Conference - ACCESS Newswire
NLS and Kadimastem move forward with merger plans By Investing.com - Investing.com Canada
NLS Gains on Deal with Kardimastem - Baystreet.ca
Kadimastem Shareholders Greenlight Merger with NLS - Sleep Review
NLS Pharmaceutics Amends Merger Agreement with Kadimastem - TipRanks
Nls Pharmaceutics Ltd Stock (NLSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):